Swedish Orphan Biovitrum AB (Sobi) issues a 5-year SEK 600 million senior unsecured bond on 26th of June 2012. The bond has a floating interest of 3 months Stibor + 500 bps with maturity in 2017 and Sobi will be applying for the loan to be listed on NASDAQ OMX Stockholm. CorpNordic Sweden has been assigned by Sobi as agent for the bond investors.
The bond will replace Sobi's existing term facility and will improve the financial flexibility as well as extend the maturity profile of Sobi's debt.
Swedish Orphan Biovitrum (Sobi) Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the health of rare disease patients and their families. The product portfolio comprises about 45 marketed products as well as projects in the late clinical phase. Key therapeutic areas are Inflammation and Genetics & Metabolism.
For more information contact Anna Litewka or Jolande Svensson-Klijn.